These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
279 related articles for article (PubMed ID: 35815721)
1. Molecular landscape of IDH-wild type, pTERT-wild type adult glioblastomas. Liu EM; Shi ZF; Li KK; Malta TM; Chung NY; Chen H; Chan JY; Poon MF; Kwan JS; Chan DT; Noushmehr H; Mao Y; Ng HK Brain Pathol; 2022 Nov; 32(6):e13107. PubMed ID: 35815721 [TBL] [Abstract][Full Text] [Related]
2. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma. Fujimoto K; Arita H; Satomi K; Yamasaki K; Matsushita Y; Nakamura T; Miyakita Y; Umehara T; Kobayashi K; Tamura K; Tanaka S; Higuchi F; Okita Y; Kanemura Y; Fukai J; Sakamoto D; Uda T; Machida R; Kuchiba A; Maehara T; Nagane M; Nishikawa R; Suzuki H; Shibuya M; Komori T; Narita Y; Ichimura K Acta Neuropathol; 2021 Aug; 142(2):323-338. PubMed ID: 34148105 [TBL] [Abstract][Full Text] [Related]
3. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma. Stichel D; Ebrahimi A; Reuss D; Schrimpf D; Ono T; Shirahata M; Reifenberger G; Weller M; Hänggi D; Wick W; Herold-Mende C; Westphal M; Brandner S; Pfister SM; Capper D; Sahm F; von Deimling A Acta Neuropathol; 2018 Nov; 136(5):793-803. PubMed ID: 30187121 [TBL] [Abstract][Full Text] [Related]
4. Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes. Labussière M; Boisselier B; Mokhtari K; Di Stefano AL; Rahimian A; Rossetto M; Ciccarino P; Saulnier O; Paterra R; Marie Y; Finocchiaro G; Sanson M Neurology; 2014 Sep; 83(13):1200-6. PubMed ID: 25150284 [TBL] [Abstract][Full Text] [Related]
5. Molecular landscape of IDH-mutant primary astrocytoma Grade IV/glioblastomas. Wong QH; Li KK; Wang WW; Malta TM; Noushmehr H; Grabovska Y; Jones C; Chan AK; Kwan JS; Huang QJ; Wong GC; Li WC; Liu XZ; Chen H; Chan DT; Mao Y; Zhang ZY; Shi ZF; Ng HK Mod Pathol; 2021 Jul; 34(7):1245-1260. PubMed ID: 33692446 [TBL] [Abstract][Full Text] [Related]
6. Molecular landscape of pediatric type IDH wildtype, H3 wildtype hemispheric glioblastomas. Hong L; Shi ZF; Li KK; Wang WW; Yang RR; Kwan JS; Chen H; Li FC; Liu XZ; Chan DT; Li WC; Zhang ZY; Mao Y; Ng HK Lab Invest; 2022 Jul; 102(7):731-740. PubMed ID: 35332262 [TBL] [Abstract][Full Text] [Related]
7. Barange M; Epari S; Gurav M; Shetty O; Sahay A; Shetty P; Goda J; Moyiadi A; Gupta T; Jalali R Neurol India; 2021; 69(1):126-134. PubMed ID: 33642283 [TBL] [Abstract][Full Text] [Related]
8. Molecular landscape of IDH-wild-type, H3-wild-type glioblastomas of adolescents and young adults. Shi ZF; Li KK; Huang QJ; Wang WW; Kwan JS; Chen H; Liu XZ; Li WC; Chan DT; Zhang ZY; Mao Y; Ng HK Neuropathol Appl Neurobiol; 2022 Jun; 48(4):e12802. PubMed ID: 35191072 [TBL] [Abstract][Full Text] [Related]
9. Diffusion and perfusion MRI may predict EGFR amplification and the TERT promoter mutation status of IDH-wildtype lower-grade gliomas. Park YW; Ahn SS; Park CJ; Han K; Kim EH; Kang SG; Chang JH; Kim SH; Lee SK Eur Radiol; 2020 Dec; 30(12):6475-6484. PubMed ID: 32785770 [TBL] [Abstract][Full Text] [Related]
10. A tailored next-generation sequencing panel identified distinct subtypes of wildtype IDH and TERT promoter glioblastomas. Higa N; Akahane T; Yokoyama S; Yonezawa H; Uchida H; Takajo T; Kirishima M; Hamada T; Matsuo K; Fujio S; Hanada T; Hosoyama H; Yonenaga M; Sakamoto A; Hiraki T; Tanimoto A; Yoshimoto K Cancer Sci; 2020 Oct; 111(10):3902-3911. PubMed ID: 32748499 [TBL] [Abstract][Full Text] [Related]
11. Clinical insights gained by refining the 2016 WHO classification of diffuse gliomas with: EGFR amplification, TERT mutations, PTEN deletion and MGMT methylation. Brito C; Azevedo A; Esteves S; Marques AR; Martins C; Costa I; Mafra M; Bravo Marques JM; Roque L; Pojo M BMC Cancer; 2019 Oct; 19(1):968. PubMed ID: 31623593 [TBL] [Abstract][Full Text] [Related]
12. IDH-wildtype lower-grade diffuse gliomas: the importance of histological grade and molecular assessment for prognostic stratification. Berzero G; Di Stefano AL; Ronchi S; Bielle F; Villa C; Guillerm E; Capelle L; Mathon B; Laurenge A; Giry M; Schmitt Y; Marie Y; Idbaih A; Hoang-Xuan K; Delattre JY; Mokhtari K; Sanson M Neuro Oncol; 2021 Jun; 23(6):955-966. PubMed ID: 33173941 [TBL] [Abstract][Full Text] [Related]
13. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624 [TBL] [Abstract][Full Text] [Related]
14. The Impact of Extensive Surgical Resection of Butterfly Glioblastomas on Outcomes in the Presence of TERT Mutation and EGFR Amplification: A Retrospective Cohort Study. Hekimoglu M; Basak AT; Akgun MY; Ozer H; Ozgen U; Maleki R; Saban D; Oktenoğlu T; Ozer AF; Sasani M Cancer Control; 2024; 31():10732748241288121. PubMed ID: 39327682 [TBL] [Abstract][Full Text] [Related]
15. Molecular Characterization of IDH Wild-type Diffuse Astrocytomas: The Potential of cIMPACT-NOW Guidelines. Kumari K; Dandapath I; Singh J; Rai HIS; Kaur K; Jha P; Malik N; Chosdol K; Mallick S; Garg A; Suri A; Sharma MC; Sarkar C; Suri V Appl Immunohistochem Mol Morphol; 2022 Jul; 30(6):410-417. PubMed ID: 35708480 [TBL] [Abstract][Full Text] [Related]
16. Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation. Kessler T; Sahm F; Sadik A; Stichel D; Hertenstein A; Reifenberger G; Zacher A; Sabel M; Tabatabai G; Steinbach J; Sure U; Krex D; Grosu AL; Bewerunge-Hudler M; Jones D; Pfister SM; Weller M; Opitz C; Bendszus M; von Deimling A; Platten M; Wick W Neuro Oncol; 2018 Feb; 20(3):367-379. PubMed ID: 29016808 [TBL] [Abstract][Full Text] [Related]
17. Comparison of Genetic Profiles and Prognosis of High-Grade Gliomas Using Quantitative and Qualitative MRI Features: A Focus on G3 Gliomas. Hong EK; Choi SH; Shin DJ; Jo SW; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SH; Won JK; Kim TM; Park CK; Kim IH; Lee ST Korean J Radiol; 2021 Feb; 22(2):233-242. PubMed ID: 32932560 [TBL] [Abstract][Full Text] [Related]
18. TERT promoter mutations and rs2853669 polymorphism: prognostic impact and interactions with common alterations in glioblastomas. Nencha U; Rahimian A; Giry M; Sechi A; Mokhtari K; Polivka M; Schmitt Y; Di Stefano AL; Alentorn A; Labussière M; Sanson M J Neurooncol; 2016 Feb; 126(3):441-6. PubMed ID: 26608520 [TBL] [Abstract][Full Text] [Related]
19. Negative prognostic impact of epidermal growth factor receptor copy number gain in young adults with isocitrate dehydrogenase wild-type glioblastoma. Hoffman DI; Abdullah KG; McCoskey M; Binder ZA; O'Rourke DM; Desai AS; Nasrallah MP; Bigdeli A; Morrissette JJD; Brem S; Bagley SJ J Neurooncol; 2019 Nov; 145(2):321-328. PubMed ID: 31542863 [TBL] [Abstract][Full Text] [Related]
20. The genomic landscape of TERT promoter wildtype-IDH wildtype glioblastoma. Diplas BH; He X; Brosnan-Cashman JA; Liu H; Chen LH; Wang Z; Moure CJ; Killela PJ; Loriaux DB; Lipp ES; Greer PK; Yang R; Rizzo AJ; Rodriguez FJ; Friedman AH; Friedman HS; Wang S; He Y; McLendon RE; Bigner DD; Jiao Y; Waitkus MS; Meeker AK; Yan H Nat Commun; 2018 May; 9(1):2087. PubMed ID: 29802247 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]